Mark Ragosa - 26 Apr 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 26 Apr 2025
Net transactions value: -$10,234
Form type: 4
Filing time: 29 Apr 2025, 16:34:06 UTC
Previous filing: 09 Apr 2025
Next filing: 01 May 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Ordinary Share	Options Exercise		+990	+3.7%		27,488	26 Apr 2025	Direct	F1
transaction	KNSA	Class A Ordinary Share	Tax liability	$10,234	-479	-1.7%	$21.36	27,009	26 Apr 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-990	-100%	$0.000000	0	26 Apr 2025	Class A Ordinary Share	990		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021.